{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:51:11Z","timestamp":1778647871774,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:00:00Z","timestamp":1525910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4479-2","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T13:04:52Z","timestamp":1525957492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-0650","authenticated-orcid":false,"given":"Michele","family":"Guida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Iole","family":"Natalicchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"De Summa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosamaria","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cramarossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Albano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Pisconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggiero","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Azzariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giusepe","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,10]]},"reference":[{"issue":"Suppl 1","key":"4479_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MJT.0b013e31829e885c","volume":"22","author":"E Espinosa","year":"2015","unstructured":"Espinosa E, Grob JJ, Dummer R, Rutkowski P, Robert C, Gogas H, Kefford R, Eggermont AM, Martin Algarra S, Hauschild A, Schadendorf D. Treatment algorithms in stage IV melanoma. Am J Ther. 2015;22(Suppl 1):61\u20137.","journal-title":"Am J Ther"},{"issue":"Suppl1","key":"4479_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(Suppl1):30\u20139.","journal-title":"N Engl J Med"},{"issue":"Suppl 20","key":"4479_CR3","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined Vemurafenib and Cobimetinib in Mutated Melanoma. N Engl J Med. 2014;371(Suppl 20):1867\u201376.","journal-title":"N Engl J Med"},{"key":"4479_CR4","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"4479_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(Suppl 1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"26","key":"4479_CR6","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"9","key":"4479_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"4479_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, JA MK, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, JL MQ, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Liz\u00e9e G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202\u201316.","journal-title":"Cancer Discov"},{"issue":"Suppl 12","key":"4479_CR9","doi-asserted-by":"publisher","first-page":"e111920","DOI":"10.1371\/journal.pone.0111920","volume":"9","author":"G Jiang","year":"2014","unstructured":"Jiang G, Li RH, Sun C, Liu YQ, Zheng J. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis. PLoS One. 2014;9(Suppl 12):e111920. https:\/\/doi.org\/10.1371\/journal.pone.0111920 .","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"4479_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13277-013-1042-2","volume":"35","author":"G Jiang","year":"2014","unstructured":"Jiang G, Li RH, Sun C, Jia HY, Lei TC, Liu YQ. Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignantmelanoma: a meta-analysis. Tumour Biol. 2014;35(Suppl 1):315\u201322.","journal-title":"Tumour Biol"},{"key":"4479_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1517\/14740338.2013.789017","volume":"5","author":"R Addeo","year":"2013","unstructured":"Addeo R, Zappavigna S, Luce A, Facchini S, Caraglia M. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opin Drug Saf. 2013;5:729\u201340.","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 23","key":"4479_CR12","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.2174\/092986712802002509","volume":"19","author":"S Mocellin","year":"2012","unstructured":"Mocellin S, Bertazza L, Benna C, Pilati P. Circumventing melanoma chemoresistance by targeting DNA repair. Curr Med Chem. 2012;19(Suppl 23):3893\u20139.","journal-title":"Curr Med Chem"},{"issue":"Suppl 5","key":"4479_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0959-8049(05)80352-1","volume":"29","author":"B Gerard","year":"1993","unstructured":"Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents-dacarbazine and fotemustine-in patients with melanoma. Eur J Cancer. 1993;29(Suppl 5):711\u20139.","journal-title":"Eur J Cancer"},{"issue":"Suppl 7","key":"4479_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1023\/A:1008304032421","volume":"10","author":"M Gander","year":"1999","unstructured":"Gander M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Li\u00e9nard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci M. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol. 1999;10(Suppl 7):831\u20138.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"4479_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s11060-010-0515-z","volume":"104","author":"P Gaviani","year":"2011","unstructured":"Gaviani P, Salmaggi A, Silvani A. Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. J Neuro-Oncol. 2011;104(Suppl 2):617\u20138.","journal-title":"J Neuro-Oncol"},{"key":"4479_CR16","first-page":"115","volume":"8","author":"M Guida","year":"2010","unstructured":"Guida M, Cramarossa A, Fistola E, Porcelli M, Giudice G, Lubello K, Colucci G. High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study J Transl Med. 2010;8:115.","journal-title":"A feasibility study J Transl Med"},{"issue":"Suppl 2","key":"4479_CR17","first-page":"293","volume":"62","author":"F Tas","year":"2008","unstructured":"Tas F, Camlica H, Topuz E. Temozolomide in combination with fotemustine in patients with metastatic melanoma. Cancer ChemotherPharmacol. 2008;62(Suppl 2):293\u20138.","journal-title":"Cancer ChemotherPharmacol"},{"issue":"Suppl 1","key":"4479_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.bjc.6603503","volume":"96","author":"JM Larkin","year":"2007","unstructured":"Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, Thomas K, Eisen TG, Gore ME. A phase I\/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer. 2007;96(Suppl 1):44\u20138.","journal-title":"Br J Cancer"},{"issue":"12","key":"4479_CR19","doi-asserted-by":"publisher","first-page":"e112025","DOI":"10.1371\/journal.pone.0112025","volume":"9","author":"VM Garrisi","year":"2014","unstructured":"Garrisi VM, Strippoli S, De Summa S, Pinto R, Perrone A, Guida G, Azzariti A, Guida M, Tommasi S. Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation. PLoS One. 2014;9(12):e112025. https:\/\/doi.org\/10.1371\/journal.pone.0112025 .","journal-title":"PLoS One"},{"key":"4479_CR20","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2007.14.5292","volume":"26","author":"P Rietschel","year":"2008","unstructured":"Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma. J ClinOncol. 2008;26:2299\u2013304.","journal-title":"J ClinOncol"},{"key":"4479_CR21","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/sj.bjc.6601270","volume":"89","author":"S Ma","year":"2003","unstructured":"Ma S, Egyh\u00e1zi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J. O6-methylguanine- DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer. 2003;89:1517\u201323.","journal-title":"Br J Cancer"},{"issue":"Suppl 12","key":"4479_CR22","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1002\/ijc.29332","volume":"136","author":"R Tuominen","year":"2015","unstructured":"Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C, Hertzman Johansson C, Lind\u00e9n D, Johansson H, Frostvik Stolt M, Walker C, Snowden H, Newton-Bishop J, Hansson J, Egyh\u00e1zi BS. MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. Int J Cancer. 2015;136(Suppl 12):2844\u201353.","journal-title":"Int J Cancer"},{"issue":"Suppl 2","key":"4479_CR23","first-page":"1105","volume":"35","author":"H Linardou","year":"2015","unstructured":"Linardou H, Pentheroudakis G, Varthalitis I, Gogas H, Pectasides D, Makatsoris T, Fountzilas G, Bafaloukos D. Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin - vinblastine - Temozolomide (PVT) as first-line treatment: a study of the Hellenic cooperative oncology group (HECOG). Anticancer Res. 2015;35(Suppl 2):1105\u201313.","journal-title":"Anticancer Res"},{"issue":"Suppl 1","key":"4479_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.bjc.6605127","volume":"101","author":"J Dunn","year":"2009","unstructured":"Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009;101(Suppl 1):124\u201331.","journal-title":"Br J Cancer"},{"issue":"Suppl 20","key":"4479_CR25","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","volume":"22","author":"MS Soengas","year":"2003","unstructured":"Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 2003;22(Suppl 20):3138\u201351.","journal-title":"Oncogene"},{"key":"4479_CR26","volume-title":"Structure and Functions of the Major Human AP Endonuclease HAP1\/Ref-1","author":"ID Hickson","year":"2000","unstructured":"Hickson ID, Gorman MA, Freemont PS. Structure and Functions of the Major Human AP Endonuclease HAP1\/Ref-1. 1st ed. Totowa: Humana Press Inc; 2000.","edition":"1"},{"issue":"Suppl 10","key":"4479_CR27","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.18632\/oncotarget.1926","volume":"5","author":"R Abbotts","year":"2014","unstructured":"Abbotts R, Jewell R, Nsengimana J, Maloney DJ, Simeonov A, Seedhouse C, Elliott F, Laye J, Walker C, Jadhav A, Grabowska A, Ball G, Patel PM, Newton-Bishop J, Wilson DM 3rd, Madhusudan S. Targeting human apurinic\/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget. 2014;5(Suppl 10):3273\u201386.","journal-title":"Oncotarget"},{"key":"4479_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/cr.2008.7","volume":"18","author":"JK Horton","year":"2008","unstructured":"Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008;18:48\u201363.","journal-title":"Cell Res"},{"issue":"Suppl 12","key":"4479_CR29","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1002\/ijc.27980","volume":"132","author":"T Abdel-Fatah","year":"2013","unstructured":"Abdel-Fatah T, Sultana R, Abbotts R, Hawkes C, Seedhouse C, Chan S, Madhusudan S. Clinicopathological and functional significance of XRCC1 expression in ovarian cancer. Inte j of cancer. 2013;132(Suppl 12):2778\u201386.","journal-title":"Inte j of cancer"},{"key":"4479_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fonc.2013.00257","volume":"3","author":"JK Horton","year":"2013","unstructured":"Horton JK, Wilson SH. Strategic combination of DNA-damaging agent and PARP inhibitor results in enhanced cytotoxicity. Front Oncol. 2013;3:257.","journal-title":"Front Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4479-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4479-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4479-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T20:48:01Z","timestamp":1604263681000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4479-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4479"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4479-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,10]]},"assertion":[{"value":"8 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We declare that this study was approved by the Ethics Committee of National Cancer Research Centre \u201cGiovanni Paolo II\u201d. All patients signed an informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflict of interest. This work was supported by MIUR PON 01_01297 \u201cVIRTUALAB\u201d; and by Onlus Association Maria Ruggieri that is supporting Sabino Strippoli\u2019s grant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"552"}}